Alivus Life Sciences cash flow

Latest FY24
Cash from operations
₹414cr+31.9% on FY23
Capital spending
₹129cr−24.2% on FY23
Free cash flow
₹285cr+98.7% on FY23
Cash from financing
−₹279cr−₹388 cr in FY23
₹ crore except per share
Tap a line for its trendLast 12Mto Sep 2026FY24Mar 2024FY23Mar 2023FY22Mar 2022
Adjustments to reconcile profit — non-cash items
—53.542.137.9
—1.50.528.0
—−12.0−15.8−6.8
Changes in working capital
—−82.6−87.9−2.8
—37.9−134−59.2
—−34.198.273.7
Cash from operating activities
888631629565
—576467736
—414313598
Cash from investing activities
—129170132
—0.50.20.5
—12.015.86.7
—−116−154−122
Cash from financing activities
———961
—2.21.61.4
———0.1
—276386129
—−279−388−78.8
—17.6−228397
Reference items
923674642616
34.4%29.5%29.7%29.0%
285285143465
——₹11.69₹39.60
—0.88×0.67×1.43×
———0.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALIVUS₹1,397.40

Alivus Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAARTIDRUGSAKUMSAGARWALEYEAPLLTDADVENZYMESAARTIPHARMCORONA
View
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Last 12M
30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation37.942.153.5—
+ Finance Costs28.00.51.5—
+ Interest Income-6.8-15.8-12.0—
Changes in Working Capital
+ Inventories-2.8-87.9-82.6—
+ Trade Receivables — Current-59.2-133.637.9—
+ Trade Payables — Current73.798.2-34.1—
Cash from Operating Activities
Profit Before Tax (per I/S)564.9628.6631.3888.4
Cash from Operations (pre-tax)735.8467.0576.5—
Cash from Operating Activities597.6313.4413.5—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)132.2170.2129.0—
+ Disp of Fixed Assets0.50.20.5—
+ Interest Received — Investing6.715.812.0—
Cash from Investing Activities-122.2-154.1-116.5—
Cash from Financing Activities
+ Proceeds from Borrowings960.6———
+ Payment of Lease Liabilities1.41.62.2—
+ Interest Paid0.1———
+ Dividends Paid128.7385.9275.7—
Cash from Financing Activities-78.8-387.6-279.4—
Net Changes in Cash396.6-228.317.6—
Reference Items
EBITDA616.1642.3674.2922.7
EBITDA Margin %29.0229.7229.5334.37
Free Cash Flow (CFO − Capex)465.4143.2284.5284.5
Free Cash Flow per Basic Share39.6011.69——
Cash Flow to Net Income1.430.670.88—
Cash Paid for Interest0.1———
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.